Neurodegenerative disease stories

Sep 29, 2026

UniQure's Huntington's gene therapy shows weaker benefit after four years

UniQure reported its gene therapy for Huntington's disease showed diminished benefits at four years compared to three years in a small trial, with shares plunging 48% as the results cast doubt on the treatment's long-term efficacy.

Sep 29, 20263 sources

Aug 25, 2026

At least 25% of former NFL players who died between 2016-2021 had CTE, study finds

A new study examining former NFL players who died recently found that at least one in four had chronic traumatic encephalopathy (CTE), the brain disease long linked to repeated head impacts in football.

Aug 25, 20262 sources

Jun 15, 2026

Brain implant enables ALS patient to communicate for nearly two years, generating 2 million words

Casey Harrell, a 42-year-old man with ALS who lost his ability to speak, has successfully used a brain-computer interface for almost three years to communicate and control his computer, producing approximately 2 million words. The at-home brain implant represents a significant milestone in assistive technology for neurodegenerative disease patients.

Jun 15, 20263 sources

May 4, 2026

Latus Bio Raises $42 Million to Advance Huntington's Disease Gene Therapy Trial

Latus Bio secured $42 million in funding as it prepares to seek FDA approval to begin a clinical trial for its gene therapy targeting Huntington's disease, a progressive neurodegenerative disorder.

May 4, 20261 source

Apr 20, 2026

Gut Microbiome Analysis Can Predict Parkinson's Disease Risk Before Symptoms Appear

New research led by University College London shows that analysis of gut microbes can reveal elevated Parkinson's disease risk before any symptoms develop, offering potential for early intervention.

Apr 20, 20261 source

Top claims

▪External control groups are reliable for evaluating experimental gene therapies
▪The FDA should approve UniQure's AMT-130 for Huntington's disease
▪UniQure NV stated that control-group patients in the AMT-130 trial who discontinued follow-up appeared to experience faster disease progression than those who remained, which may have understated the potential benefit of AMT-130

Subtopics

Drug Approval and Clinical Trials4 Clinical trials2 Gene therapy2 Alzheimer’s & dementia1 Assistive technology.1 Biomarkers & bloodwork testing1 Brain-computer interfaces1 Gut health & microbiome1 Lifestyle, Wellness and Nutrition1 Medical implants1 Mental health1 NFL1 Pharma1 Public health1

Related timelines